赛隆药业(002898) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥79,427,813.05, representing a 27.68% increase compared to ¥62,208,999.46 in the same period last year[4] - Net profit attributable to shareholders for Q1 2023 was ¥3,197,374.56, a significant increase of 149.63% from ¥1,280,860.47 in the previous year[4] - The net profit excluding non-recurring gains and losses was ¥937,954.39, compared to a loss of ¥2,162,519.46 in the same period last year, marking a 143.37% improvement[4] - The basic earnings per share for Q1 2023 was ¥0.0182, up 149.32% from ¥0.0073 in the previous year[4] - Total operating revenue for Q1 2023 was CNY 79,427,813.05, an increase of 27.6% compared to CNY 62,208,999.46 in Q1 2022[15] - Net profit for Q1 2023 reached CNY 3,197,374.56, representing a significant increase of 149.9% from CNY 1,280,860.47 in Q1 2022[16] - Basic and diluted earnings per share for Q1 2023 were CNY 0.0182, compared to CNY 0.0073 in the same period last year, marking an increase of 149.3%[17] Cash Flow and Investments - The company's cash flow from operating activities improved by 70.84%, with a net outflow of ¥5,552,217.03 compared to ¥19,037,470.33 in the same period last year[4] - Cash flow from investing activities increased by 129.30%, driven by higher fixed asset investments during the quarter[7] - The total cash inflow from operating activities was CNY 69,222,319.23, compared to CNY 43,941,902.00 in the same period last year, reflecting a growth of 57.5%[18] - The net cash flow from investment activities was -5,116,248.02, compared to -2,231,243.99 in the previous year, indicating a significant increase in cash outflow for investments[20] - The cash outflow for the acquisition of fixed assets, intangible assets, and other long-term assets was 5,188,807.95, compared to 5,820,680.42 in the previous year[20] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥827,259,456.27, a decrease of 2.44% from ¥847,991,091.15 at the end of the previous year[4] - Current assets decreased to CNY 236,594,634.75 from CNY 254,357,080.25 at the beginning of the year[11] - Cash and cash equivalents decreased to CNY 47,343,347.90 from CNY 72,269,804.86 at the beginning of the year[11] - The company's total liabilities as of Q1 2023 were CNY 297,713,389.58, a decrease from CNY 321,642,399.02 in Q1 2022[16] - Total current liabilities decreased to CNY 242,231,470.19 from CNY 296,451,407.07 at the beginning of the year[12] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,662[8] - The largest shareholder, Cai Nanguai, holds 51.15% of the shares, totaling 90,016,937 shares, with 67,512,703 shares pledged[8] Research and Development - Research and development expenses rose by 75.66%, reflecting increased investment in R&D activities[7] - Research and development expenses for Q1 2023 totaled CNY 7,277,255.13, up from CNY 4,142,780.79 in the previous year, indicating a 75.5% increase[15] Other Financial Metrics - The company reported a fair value change gain of CNY 1,975,851.43 in Q1 2023, down from CNY 4,020,856.24 in Q1 2022[16] - The ending cash and cash equivalents balance was 46,377,644.90, down from 89,272,183.43 in the previous year, indicating a decrease in liquidity[20] - The company did not conduct an audit for the first quarter report, which may affect the perception of financial reliability[21]